Searchable abstracts of presentations at key conferences in endocrinology

ea0063p1067 | Pituitary and Neuroendocrinology 3 | ECE2019

A closer look at pituitary deficiency in Ipilimumab-induced hypophysitis

Stormann Sylvere Schilbar Katharina , Kuppers Anna , Schopohl Jochen , Stormann Sylvere

Introduction: Ipilimumab is a monoclonal antibody directed against CTLA-4 used primarily in treatment of malignant melanoma. Immunological side effects are common, amongst others it may lead to hypophysitis. We studied clinical characteristics of IpiH and compared it to cases of primary hypophysitis (PH).Methods: We conducted a retrospective single centre study in 75 hypophysitis patients (60 primary, 15 Ipilimumab-induced in patients with melanoma). Gro...

ea0063p252 | Pituitary and Neuroendocrinology 1 | ECE2019

A case of ‘micromegaly’: need for revision of oral glucose tolerance test (OGTT) cut-offs with modern growth hormone assays in acromegaly

Schilbach Katharina , Stormann Sylvere , Bidlingmaier Martin , Schopohl Jochen

The OGTT is the gold standard for confirmation or exclusion of acromegaly in treatment-naïve patients as well as after surgery. According to former guidelines, acromegaly is ruled out if the growth hormone (GH) nadir lies below 1.0 μg/l and 0.4 μg/l pre- and postoperatively, respectively. We present the case of a 40-year-old man who presented to the outpatient clinic in 2014 for endocrinological evaluation after an elevated IGF-I concentration had occasionally b...

ea0037ep815 | Pituitary: clinical | ECE2015

Renal function in acromegaly

Pichl Christine , Stormann Sylvere , Pichler Matthias , Schopohl Jochen

Introduction: Acromegaly is a rare disease resulting from GH excess mostly due to pituitary adenomas. It is associated with changes of most organ systems and multiple comorbidities. The impact of GH and IGF-I excess on renal function in acromegaly is unclear.Methods: We investigated 66 acromegalic patients from our outpatient clinic (32 female, 34 male, mean age 61.5±12.9 years, women 10 years older than men). The renal function was assessed by bloo...

ea0056p707 | Clinical case reports - Pituitary/Adrenal | ECE2018

Atypical pituitary adenoma: a case of histological mimicry

Schilbach Katharina , Saeger Wolfgang , Stormann Sylvere , Schopohl Jochen

We present the case of a 67-year-old man who presented to the outpatient clinic for endocrinological evaluation after partial resection of an atypical pituitary adenoma (APA). Pathohistological assessment of two independent and experienced neuropathologists resulted in a diagnosis of APA with unusually high proliferation indices (Ki67 10–20%/p53 30%) and immunoreactivity for LH, FSH and the alpha-subunit. Clinical examination as well as laboratory testing revealed no sign...

ea0081ep692 | Pituitary and Neuroendocrinology | ECE2022

Soluble alpha klotho in blood is a new and highly stable biomarker

Ribeiro de Oliveira Longo Schweizer Junia , Haenelt Michael , Schilbach Katharina , Stormann Sylvere , Schopohl Jochen , Bidlingmaier Martin

Background: Soluble alpha klotho (sαKL) is a circulating protein that has been linked to the growth hormone (GH) axis. We previously showed its association to disease activity in patients with acromegaly, with considerable robustness towards biological confounders. However, there is scarce data in literature regarding the analytical performance of the assay, and pre-analytical stability of sαKL in blood samples. Objective: We aimed to evaluate ...

ea0081ep715 | Pituitary and Neuroendocrinology | ECE2022

Growth hormone leading to faster recovery in pure motor Guillain-Barre syndrome: report of the first off-label use in one patient

Amereller Felix , Jochen Schopohl , Sylvere Stormann , Martin Bidlingmaier , Peter Rieckmann , Philipp Gulde

Background: Although the prognosis inGuillain-Barré syndrome (GBS) is generally good, the protracted and sometimes incomplete recovery is a heavy burden for patients. Animal studies suggest that treatment with growth hormone (GH) could stimulate myelin repair and thus accelerate functional recovery in acute polyneuropathy. We report on the first use of GH in GBS.Objective: To monitor safety and tolerability as well as to evaluate the effect of off-l...

ea0090ep761 | Pituitary and Neuroendocrinology | ECE2023

Delayed onset of pasireotide-induced hyperglycemia: Report of two cases

Stormann Sylvere , Schilbach Katharina , Amereller Felix , Schweizer Junia Ribeiro de Oliveira Longo , Schopohl Jochen

Introduction: Pasireotide is a potent somatostatin analogue (SSA) and used in therapy-refractory acromegaly, commonly after failure of treatment with first-generation SSA. However, it may induce severe hyperglycemia, which usually occurs rapidly after initiation of therapy and in general gradually improves over time. We here present two cases of young male patients who developed severe pasireotide-induced hyperglycemia after several years of treatment.Ca...

ea0049ep1027 | Pituitary - Clinical | ECE2017

Potassium homeostasis in patients with acromegaly in comparison with hypertensive patients

Stormann Sylvere , Schilbach Katharina , Pichl Christine , Kosilek Robert P , Anders Hans-Joachim , Schopohl Jochen

Introduction: Acromegaly is characterized by chronic growth hormone (GH) excess and leads to numerous changes in bodily functions and comorbidity. We compared potassium homeostasis in patients with acromegaly to hypertensive controls.Methods: We prospectively assessed serum potassium, urinary potassium excretion, aldosterone and renin, acid-base balance as well as glomerular filtration rate according to the CKD-EPI formula in 71 patients with acromegaly ...

ea0041ep860 | Pituitary - Basic | ECE2016

Evidence for better response to somatostatin analogues in acromegalic patients treated with metformin

Winkelmann Moritz , Geraedts Victor , Lucia Kristin , Stormann Sylvere , Buchfelder Michael , Stalla Gunter , Theodoropoulou Marily

Somatostatin analogues (SSA) are the mainstay of pituitary-targeted pharmacological treatment in acromegaly, but are characterized by high incidence of resistance in half of cases. The successful management of acromegaly involves in addition to targeting biochemical control the treatment of the metabolic comorbidities and hypopituitarism. In this study we analysed the impact of the concomitant antidiabetic treatment and hormone replacement on the response to SSA. Data were col...

ea0037ep765 | Pituitary: clinical | ECE2015

Effectiveness and tolerability of lanreotide in acromegaly: a German database analysis

Dimopoulou Christina , Stormann Sylvere , Schopohl Jochen , Faust Johanna , Stalla Gunter Karl

Introduction: Somatostatin analogues (SSA) present the treatment of choice in patients with previously poorly controlled acromegaly.Methods: We conducted a retrospective analysis of acromegalic patients enrolled in the Network of Excellence for Neuroendocrine Tumors Munich and treated with the SSA lanreotide.Results: Fifty-six acromegalic patients (25 females; mean age 59 years; 33 with macroadenoma) switched to lanreotide from pre...